RESEARCHER PROFILE
Professor Stuart Brierley (Filmed February 2024)
Director of the Visceral Pain Research Group,
Director of the Hopwood Centre for Neurobiology &
Theme co-Leader of Lifelong Health
South Australian Health and Medical Research Institute (SAHMRI)
Professor Stuart Brierley is Director of the Visceral Pain Research Group, Director of the Hopwood Centre for Neurobiology, and Theme co-Leader of Lifelong Health at the South Australian Health and Medical Research Institute (SAHMRI).
He has developed a strong track record in coordinating and working in multi-faceted research programs for high impact publications in journals. His work has attracted four NHMRC Fellowships including other NHMRC and NIH grants.
The global pandemic has shed light on the severity of the Opioid Crisis, highlighting the urgent need for effective pain treatments. During his 24 years as a researcher, Professor Brierley has made significant strides in understanding how pain arises from the gastrointestinal tract or the gut.
Prof Brierley is an international expert on the ‘gut-brain axis’ and chronic visceral pain mechanisms. Current investigations are on a individual cell type called the enterochromaffin cell, and it helps signal pain and anxiety from the gastrointestinal tract to the brain.
His research comprises discovery and translational science investigating the nerve pathways innervating visceral organs to determine the causes of, and treatments for, Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), bladder pain syndrome, and endometriosis.
Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) disorders are highly prevalent, affecting up to 15% of the Western population.
Despite being a major global clinical issue, pain, especially from the gastrointestinal tract, lacks effective treatments, and the research focuses on understanding and treating pain in gastrointestinal diseases in order to develop targeted treatments. Individual gut cells communicate with the brain to signal pain and trigger symptoms that include depression and anxiety.
Professor Brierley is collaborating with researchers in Australia and internationally including Nobel Prize winner Nobel Prize Laureate Professor David Julius, Professor Holly Ingraham and Dr Jim Bayrer at the University of California San Francisco, all with the goal of helping people.
His research interests extends into other common causes for visceral pain including interstitial cystitis/painful bladder syndrome and endometriosis and how ‘cross-organ sensitisation’ can potentially explain co-morbidities in these patients.
Pain is a global issue, and Professor Brierley’s work aims to understand its causes in order to develop targeted treatments, while also balancing a busy family life and various interests.
You Might also like
-
Next-generation NK cell-based immunotherapies for hard-to-treat cancers
Associate Professor Fernando Guimaraes is an internationally recognised leader in cancer immunotherapy and natural killer (NK) cell biology. Based at The University of Queensland, he leads innovative research focused on developing next-generation NK cell-based immunotherapies for hard-to-treat cancers, including sarcomas and neuroblastoma.
-
Novel immunotherapies in lymphoma
Dr Sean Harrop is a dual-trained haematologist having completed his clinical and laboratory haematology training at the Peter MacCallum Cancer Centre, Royal Melbourne Hospital and St Vincent’s Hospital Melbourne. He is the current clinical haematology fellow (aggressive lymphoma) at Peter MacCallum and a PhD student in the Cancer Immunology Program in the Neeson Lab.
-
CASE STUDY Role of Exercise in Metabolic Associated Fatty Liver Disease
Dr. Shelley Keating AES AEP* is an Accredited Exercise Physiologist, a researcher, and a senior lecturer at the School of Human Movement and Nutrition Sciences at the University of Queensland in Brisbane, Australia. Dr. Keating’s research primarily focuses on the role of exercise in the management of metabolic dysfunction associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease. MASLD affects a significant portion of the global adult population, with many individuals unaware of their condition.